DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 189.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,289 shares of the medical device company's stock after buying an additional 42,718 shares during the period. Quantinno Capital Management LP's holdings in DexCom were worth $5,078,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Private Trust Co. NA increased its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the fourth quarter valued at $33,000. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC raised its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DXCM. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Finally, Barclays raised their price target on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $98.11.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. This represents a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is currently owned by corporate insiders.

DexCom Trading Down 2.8%

Shares of DXCM stock traded down $2.45 during trading on Wednesday, hitting $84.89. 2,673,172 shares of the stock traded hands, compared to its average volume of 4,352,467. The firm has a market capitalization of $33.29 billion, a P/E ratio of 59.36, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $131.76. The firm's fifty day moving average price is $72.71 and its 200-day moving average price is $77.87.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm posted $0.32 EPS. The company's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.